Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Patients With High Blood Pressure and High Cholesterol

tiistai 5. toukokuuta 2026 päivittänyt: Celltrion Pharm, Inc.

A Multi-center, Randomized, Double-blind, Active-controlled, Phase III Trial to Evaluate the Efficacy and Safety of Ezetimibe/Rosuvastatin and Amlodipine Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia

The goal of this clinical trial is to test whether one pill that combines ezetimibe, rosuvastatin, and amlodipine can safely lower cholesterol and blood pressure in Korean adults with high blood pressure and high cholesterol.

Tutkimuksen yleiskatsaus

Tila

Valmis

Ehdot

Interventio / Hoito

Yksityiskohtainen kuvaus

Amlodipine is a calcium channel blocker used for the treatment of hypertension. Rosuvastatin is a statin that inhibits HMG-CoA reductase and is widely used for the treatment of hypercholesterolemia. Ezetimibe is a lipid-lowering agent that inhibits intestinal cholesterol absorption and is commonly used in combination with statins.

This multicenter, randomized, double-blind, active-controlled, phase 3 clinical trial evaluates the efficacy and safety of a fixed-dose combination of ezetimibe, rosuvastatin, and amlodipine in Korean adults with essential hypertension and primary hypercholesterolemia. Following a run-in period that includes therapeutic lifestyle modification, participants are randomized in a 1:1:1 ratio to receive ezetimibe/rosuvastatin/amlodipine 10/20/10 mg or amlodipine 10 mg, or ezetimibe/rosuvastatin 10/20 mg for 8 weeks.

A total of 163 participants were enrolled across 21 study sites. Low-density lipoprotein cholesterol (LDL-C) levels and mean sitting systolic blood pressure (MSSBP) are assessed at Weeks 4 and 8. The primary efficacy endpoints are the percent change in LDL-C from baseline at Week 8 and the change in MSSBP from baseline at Week 8. Secondary endpoints include changes in total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, and apolipoprotein B (ApoB).

Opintotyyppi

Interventio

Ilmoittautuminen (Todellinen)

163

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskelupaikat

  • Etelä -Korea
      • Ansan, Etelä -Korea
        • Korea University Ansan Hospital
      • Anyang, Etelä -Korea
        • Hallym University Sacred Heart Hospital
      • Busan, Etelä -Korea
        • Kosin University Gospel Hospital
      • Busan, Etelä -Korea
        • Pusan National University Hospital
      • Cheonan, Etelä -Korea
        • Dankook University Hospital
      • Daegu, Etelä -Korea
        • Keimyung University Dongsan Medical Center
      • Daegu, Etelä -Korea
        • Yeungnam University Hospital
      • Daegu, Etelä -Korea
        • Daegu Catholic University Medical Center
      • Gwangju, Etelä -Korea
        • Chonnam National University Hospital
      • Incheon, Etelä -Korea
        • Gachon University Gil Medical Center
      • Jeonju, Etelä -Korea
        • Jeonbuk National University Hospital
      • Seongnam, Etelä -Korea
        • CHA University Bundang Medical Center
      • Seoul, Etelä -Korea
        • Asan Medical Center
      • Seoul, Etelä -Korea
        • Kangbuk Samsung Hospital
      • Seoul, Etelä -Korea
        • Korea University Anam Hospital
      • Seoul, Etelä -Korea
        • Korea University Guro Hospital
      • Seoul, Etelä -Korea
        • Severance Hospital
      • Seoul, Etelä -Korea
        • The Catholic University of Korea Seoul St. Mary's Hospital
      • Seoul, Etelä -Korea
        • Nowon Eulji Medical Center, Eulji University
      • Uijeongbu-si, Etelä -Korea
        • Uijeongbu Eulji Medical Center, Eulji University
      • Uijeongbu-si, Etelä -Korea
        • The Catholic University of Korea Uijeongbu St. Mary's Hospital

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Screening Inclusion Criteria:

  • Age 19 years or older at the time of written informed consent
  • Diagnosed with essential hypertension and primary hypercholesterolemia, or currently receiving antihypertensive and/or lipid-lowering medication after such diagnosis
  • If receiving antihypertensive and/or lipid-lowering therapy at screening, judged by the investigator to be medically appropriate for discontinuation of prior therapy during the clinical trial period
  • Able and willing to voluntarily sign the written informed consent form after receiving an explanation of the purpose, methods, and expected effects of the study

Randomization Inclusion Criteria:

  • Mean sitting systolic blood pressure (MSSBP) of at least 140 mmHg and less than 180 mmHg, and mean sitting diastolic blood pressure (MSDBP) less than 110 mmHg
  • Completion of at least 4 weeks of therapeutic lifestyle modification before administration of the investigational product
  • After at least 4 weeks of therapeutic lifestyle modification, fasting LDL-C meeting one of the following criteria:
  • Very high-risk group: LDL-C 70 mg/dL or higher in participants with coronary artery disease, atherosclerotic ischemic stroke or transient ischemic attack, or peripheral arterial disease
  • High-risk group: LDL-C 100 mg/dL or higher in participants with carotid artery disease, abdominal aneurysm, or diabetes mellitus
  • Moderate-risk group: LDL-C 130 mg/dL or higher in participants with 2 or more major risk factors
  • Low-risk group: LDL-C 160 mg/dL or higher in participants with 1 or fewer major risk factors
  • Fasting triglycerides less than 400 mg/dL and LDL-C 250 mg/dL or lower

Exclusion Criteria:

  • MSSBP ≥ 180 mmHg or MSDBP ≥ 110 mmHg at screening or randomization
  • Difference between arms at screening of MSSBP ≥ 20 mmHg and MSDBP ≥ 10 mmHg
  • History of secondary hypertension or medical history suggestive of secondary hypertension, including coarctation of the aorta, hyperaldosteronism, renal artery stenosis, Cushing disease, pheochromocytoma, or polycystic kidney disease, etc.
  • Symptomatic orthostatic hypotension, defined as a decrease in systolic blood pressure of 20 mmHg or more or diastolic blood pressure of 10 mmHg or more on standing compared with sitting or supine blood pressure
  • Subjects with secondary dyslipidemia
  • Severe cardiac disease, including congestive heart failure (NYHA class III or IV), clinically significant arrhythmia, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, or hemodynamically significant stenosis of the aortic or mitral valve
  • Unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or percutaneous coronary intervention within 6 months prior to screening
  • Retinal hemorrhage, including visual impairment, within 6 months prior to screening
  • Chronic inflammatory disease requiring treatment (e.g., rheumatoid arthritis), or wasting disease, autoimmune disease, or connective tissue disease
  • Endocrine or metabolic disease known to affect serum lipids or lipoproteins, including uncontrolled diabetes mellitus (HbA1c > 9%) or uncontrolled thyroid dysfunction (TSH > 1.5 times the upper limit of normal)
  • Severe renal or hepatic impairment, defined as AST or ALT > 3 times the upper limit of normal, or serum creatinine > 1.5 times the upper limit of normal
  • History of myopathy or rhabdomyolysis, or creatine kinase (CK) > 2 times the upper limit of normal
  • Patients who received, before study participation, treatment with medications that may affect lipid levels, including bile acid sequestrants, anti-obesity medications, fibrates, niacin, or systemic steroid therapy; however, participation is permitted if the relevant washout period has been completed.
  • Need for treatment with protocol-prohibited concomitant medications during the study period
  • History of hypersensitivity to ezetimibe, rosuvastatin, amlodipine, or related drug classes
  • Patients with gastrointestinal disease or a history of surgery that may affect drug absorption, distribution, metabolism, or excretion, including current active gastritis, gastrointestinal or rectal bleeding, a history of major gastrointestinal surgery, a history of active inflammatory bowel disease within 12 months before screening, or hereditary disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • History of drug or alcohol abuse
  • Pregnant or breastfeeding participants, or participants unwilling to use appropriate contraception during the study period
  • History of malignancy within 5 years before screening, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or carcinoma in situ of other sites, provided that the disease was successfully treated and there has been no recurrence for at least 3 years; enrollment may be considered at the investigator's medical discretion.
  • Use of another investigational product within 4 weeks prior to screening
  • Any other condition or circumstance that, in the investigator's judgment, would make the participant unsuitable for study participation

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Nelinkertaistaa

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Amlodipine, Ezetimibe/Rosuvastatin
Lääke: Amlodipine
Oral tablet containing amlodipine 10 mg administered for 8 weeks.
Lääke: Ezetimibe/Rosuvastatin
Fixed-dose combination oral tablet containing ezetimibe 10 mg and rosuvastatin 20 mg administered for 8 weeks.
Active Comparator: Amlodipine, Ezetimibe/Rosuvastatin placebo
Lääke: Amlodipine
Oral tablet containing amlodipine 10 mg administered for 8 weeks.
Lääke: Ezetimibe/Rosuvastatin Placebo
Placebo for ezetimibe/rosuvastatin (10mg/20mg)
Active Comparator: Amlodipine placebo, Ezetimibe/Rosuvastatin
Lääke: Ezetimibe/Rosuvastatin
Fixed-dose combination oral tablet containing ezetimibe 10 mg and rosuvastatin 20 mg administered for 8 weeks.
Lääke: Amlodipine Placebo
Placebo for amlodipine (10mg)

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 8 in Treatment Group and Control Group 1
Aikaikkuna: Baseline, Week 8
Percent change from baseline in LDL-C level.
Baseline, Week 8
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 8 in Treatment Group and Control Group 2
Aikaikkuna: Baseline, Week 8
Change from baseline in mean sitting systolic blood pressure. Change is calculated as the Week 8 value minus the baseline value.
Baseline, Week 8

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 4 in the Treatment Group and Control Group 1
Aikaikkuna: Baseline, Week 4
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Week 4 in the treatment group and control group 1.
Baseline, Week 4
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Week 4 in the Treatment Group and Control Group 2
Aikaikkuna: Baseline, Week 4
Change from baseline in mean sitting systolic blood pressure (MSSBP) at Week 4 in the treatment group and control group 2.
Baseline, Week 4
Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) at Weeks 4 and 8 in the Treatment Group and Control Group 1
Aikaikkuna: Baseline, Week 4, Week 8
Change from baseline in mean sitting systolic blood pressure (MSSBP) at Weeks 4 and 8 in the treatment group and control group 1.
Baseline, Week 4, Week 8
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group and Control Group 2
Aikaikkuna: Baseline, Week 4, Week 8
Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group and control group 2.
Baseline, Week 4, Week 8
Percent Change From Baseline in TC, TG, HDL-C, non-HDL-C, and Apo B at Weeks 4 and 8 in the Treatment Group, Control Group 1 and Control Group 2
Aikaikkuna: Baseline, Week 4, Week 8
Percent change from baseline in total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (Apo B) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.
Baseline, Week 4, Week 8
Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
Aikaikkuna: Baseline, Week 4, Week 8
Change from baseline in mean sitting diastolic blood pressure (MSDBP) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2.
Baseline, Week 4, Week 8
Proportion of Participants Achieving Target Blood Pressure at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
Aikaikkuna: Week 4, Week 8
Proportion of participants who achieved target blood pressure at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target blood pressure is defined as MSSBP/MSDBP <140/90 mmHg. For participants with high-risk diabetes mellitus, chronic kidney disease with diabetes mellitus or albuminuria, concomitant cardiovascular disease, or high-risk hypertension, target blood pressure is defined as MSSBP/MSDBP <130/80 mmHg.
Week 4, Week 8
Proportion of Participants Achieving Target Low-Density Lipoprotein Cholesterol (LDL-C) at Weeks 4 and 8 in the Treatment Group, Control Group 1, and Control Group 2
Aikaikkuna: Week 4, Week 8
Proportion of participants who achieved target low-density lipoprotein cholesterol (LDL-C) at Weeks 4 and 8 in the treatment group, control group 1, and control group 2. Target LDL-C is defined according to cardiovascular risk category as follows: very high-risk, <70 mg/dL; high-risk, <100 mg/dL; moderate-risk, <130 mg/dL; and low-risk, <160 mg/dL.
Week 4, Week 8

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Celltrion Pharm, Inc.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 5. elokuuta 2022

Ensisijainen valmistuminen (Todellinen)

Tiistai 13. helmikuuta 2024

Opintojen valmistuminen (Todellinen)

Tiistai 13. helmikuuta 2024

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 27. huhtikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 27. huhtikuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 4. toukokuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Perjantai 8. toukokuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Tiistai 5. toukokuuta 2026

Viimeksi vahvistettu

Perjantai 1. toukokuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Avainsanat

Muita asiaankuuluvia MeSH-ehtoja

Muut tutkimustunnusnumerot

  • CTP-EAR 3.1

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

EI

IPD-suunnitelman kuvaus

This completed study is being registered retrospectively, and no prospective plan for IPD sharing was specified in the original protocol.

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa